Cellular Therapies tissue manipulation and clinical solutions Cell Therapies
 
Home
About
Facilities
Our Staff
News + Developments
Studies + Trials
Media + Publications
Cell Therapies delivers flexible solutions across the full spectrum of clinical trials involving cell and tissue manipulation
 
 
Cell Therapies can provide a one-stop shop

Cell Therapies can provide a one-stop shop for those organisations seeking to run Phase 2/3/4 trials. Our capacity to work with a wide range of cell types and clinical conditions has proven to be a powerful attraction for our clients. We are able to recruit patients from both within our facility and/or in collaboration with other clinical sites. We are able to deliver reliable trial results under demanding protocols and reporting regimens.
Fully licensed facilities |

Cell Therapies provides a one-stop shop for those organisations seeking to run Phase 2/3/4 trials

Of critical interest to clinical trial sponsors, is the seamless integration of our cell collection, processing and manipulation capabilities with Peter Mac’s state of the art Diagnostic Imaging suite (PET, MRI, CT, SPECT, combined PET-CT, Ultrasound and small animal imaging) and Clinical Divisions of Haematology, Medical Oncology, Radiation Oncology and Surgery.
Special laboratory features |

Services Provided and Clinical Trials Supported
Trial or Service Cell Type Disease
DC vaccine utilising autologous tumor lysate Dendritic Cells Myeloma
Gene Engineered T-lymphocytes transduced with anti-LewisY chimeric receptor T-cells AML
Production of tissue for repair of focal defect in cartilage (TGA Licence) chondrocytes Osteoarthritis
Facilities and support JDRF/Federal Govt. Sponsored Islet replacement Islets Diabetes
Two part (CTX) Hep-C Trial involving autologous DC and i) a synthetic Lipopeptide and ii) the use of an HCV-specific mRNA. Dendritic Cells Hepatitis C
Autologous marrow derived and purified prior to expansion Mesenchymal Precursor Cells (MPC) MPC’s Cardiac regeneration
Autologous marrow derived and purified prior to expansion Mesenchymal Precursor Cells (MPC) MSC’s Bone Repair
Dendritic Cell Vaccine for MUC-1 positive ovarian cancer Dendritic cells Ovarian Cancer
Process development for novel methods for antigen presentation and T-Cell selection & expansion T-cells N/A
Support of licensed tissue and blood procurement from interstate and local sites all N/A
Autologous Monocyte-derived activated killer cells (MAK) MAK cells Ovarian cancer
MAK cell production + human in vivo SPECT/PET-CT tracking MAK cells Ovarian cancer
Autologous Dendritic cell therapy for Myeloma Dendritic cells Myeloma
Autologous Dendritic cell therapy for Melanoma Dendritic cells Melanoma
Autologous Dendritic cell therapy for MUC-1 positive tumors Dendritic cells Lung & Breast Cancer
Ex vivo expansion of blood stem cells Blood stem cells Breast cancer
Autologous derived IL-2 receptor agonist Mononuclear cells Osteoarthritis
Chondrocyte growth chondrocytes Osteoarthritis
Facility Management, Protocol & SOP Development All N/A
DC cell production + human in vivo SPECT/PET-CT tracking Dendritic Cells myeloma
DC ell production+ human in mouse PET and auto-radiographic tracking Dendritic cells N/A
Standard of care collection, production and local interstate banking of autologous PBSC (TGA licence) PBSC Haematological Malignancies
Production and testing of novel tracking agents for human cell therapy for bio-distribution & persistence studies All N/A
 
 
Cellular Therapies tissue manipulation and clinical solutions Cell Therapies | Contact | Login | Site ex99elle
In association with Peter MacCallum Cancer Research - Genetics, Genomics and Biotechnology BioMelbourne Network - Progressing BioIndustry
Cell Therapies Pty Ltd ABN 100 285 916